FBRX Summary

  1. NASDAQ
  2. >
  3. FBRX
TickerFBRX
DescriptionFORTE BIOSCIENCES INC
Forte Biosciences, Inc. is a clinical stage, dermatology company developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and pediatric (3 years of age and older) patients with atopic dermatitis. There is a significant unmet need for safe and effective therapies particularly for pediatric atopic dermatitis patients. In September 2020, Forte initiated a multi-center, placebo controlled clinical trial of FB-401 which is expected to enroll pediatric, adolescent and adult AD subjects aged 2 years of age and older.
ExchangeNASDAQ
TypeStock
SectorHealthcare
Employees9
Next Earnings DateAugust 9th, 2021
IV266.601119%
IV Percentile99th
IV Rank100.00%
IV Skew6.727595
IV Skew Percentile60th
IV Skew SentimentNeutral
Option Volume1,729
Volume204,574
Price$29.96
Previous Close$29.98
52-Week High$53.99
52-Week Low$17.90
50-Day Moving Avg.$34.66
200-Day Moving Avg.$34.15
10-Day Avg. Volume266,112
20-Day Avg. Volume221,049
30-Day Avg. Volume227,395
3-Month Avg. Volume188,612
EPS-$5.71
Outstanding Shares13,511,716
Market Capitalization$419,944,100
CurrencyUSD
UpdatedJuly 30th, 2021